Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11756412
Li Y, Dowbenko D, Lasky LA (2002) AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 277, 11352-61 11756412
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T145-p - p21Cip1 (human)
Modsite: QGRkRRQtsMTDFyH SwissProt Entrez-Gene
Orthologous residues
p21Cip1 (human): T145‑p, p21Cip1 (mouse): T140‑p, p21Cip1 (dog): T113‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
Relevant cell lines - cell types - tissues:  293E (epithelial), A172 (glial), T98G (glial), U-118MG (glial), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) transfection of constitutively active enzyme, transfection of inactive enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 serum inhibit treatment-induced increase
taxol increase
LY294002 taxol inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PCNA (human) Disrupts co-immunoprecipitation

S146-p - p21Cip1 (human)
Modsite: GRkRRQtsMTDFyHs SwissProt Entrez-Gene
Orthologous residues
p21Cip1 (human): S146‑p, p21Cip1 (mouse): S141‑p, p21Cip1 (dog): S114‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
Relevant cell lines - cell types - tissues:  293E (epithelial), A172 (glial), T98G (glial), U-118MG (glial), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) transfection of constitutively active enzyme, transfection of inactive enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
LY294002 serum inhibit treatment-induced increase
taxol increase
LY294002 taxol inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  protein stabilization